← Back to Clinical Trials
Recruiting NCT04462458

NCT04462458 M-ARS ACL Post-marketing Surveillance Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04462458
Status Recruiting
Phase
Sponsor Medacta International SA
Condition Anterior Cruciate Ligament (ACL) Reconstruction
Study Type OBSERVATIONAL
Enrollment 200 participants
Start Date 2022-07-01
Primary Completion 2025-07

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Medacta Anatomic Ribbon Surgery (M-ARS ACL)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 200 participants in total. It began in 2022-07-01 with a primary completion date of 2025-07.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study is to evaluate the performance of Medacta Anatomic Ribbon Surgery (M-ARS) in patients requiring anterior cruciate ligament (ACL) reconstruction. The main goal is to evaluate the survival rate of M-ARS ACL at 6 months post-operatively. The secondary goals are to assess the survival rate, clinical and functional outcomes, the quality of life, and the rate of complications at 1 month, 1 year and 2 years post-operatively.

Eligibility Criteria

Inclusion Criteria: * Patients older than 18 years * Patients with ACL rupture requiring ACL reconstruction Exclusion Criteria: * Patients with malignant diseases (at the time of surgery) * Patients with proven or suspected infections (at the time of surgery) * Patients with functional deficits of the affected extremity (at the time of surgery) * Patients with known incompatibility or allergy to products materials (at the time of surgery)

Contact & Investigator

Central Contact

Denise Falcone

✉ falcone@medacta.ch

📞 +41916966060

Principal Investigator

Mirco Herbort, Prof. Dr. med.

PRINCIPAL INVESTIGATOR

OCM Klinik GmbH

Frequently Asked Questions

Who can join the NCT04462458 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Anterior Cruciate Ligament (ACL) Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04462458 currently recruiting?

Yes, NCT04462458 is actively recruiting participants. Contact the research team at falcone@medacta.ch for enrollment information.

Where is the NCT04462458 trial being conducted?

This trial is being conducted at Innsbruck, Austria, Kirchdorf an der Krems, Austria, München, Germany.

Who is sponsoring the NCT04462458 clinical trial?

NCT04462458 is sponsored by Medacta International SA. The principal investigator is Mirco Herbort, Prof. Dr. med. at OCM Klinik GmbH. The trial plans to enroll 200 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology